|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Product revenues, net | |||||
| Costs and expenses: | |||||
| Selling, general and administrative | |||||
| General and administrative | |||||
| Research and development | |||||
| (Gain) loss on fair value remeasurement of deferred purchase consideration | |||||
| Gain on fair value remeasurement of deferred purchase consideration | |||||
| (Gain) loss on fair value remeasurement of contingent consideration | |||||
| Impairment of right-of-use assets | |||||
| Total costs and expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Interest income | |||||
| Interest expense | |||||
| Grant income | |||||
| Gain on extinguishment of debt | |||||
| Other income (expense), net | |||||
| Total other income (expense) | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Total comprehensive loss | |||||
| Net loss per share attributable to common stockholders-basic (in dollar per share) | |||||
| Net loss per share attributable to common stockholders-diluted (in dollar per share) | |||||
| Weighted average shares outstanding-basic (in shares) | |||||
| Weighted average common shares outstanding -diluted (in shares) | |||||
Loading...